Anti-PD-1 (Nivolumab), Humanized Antibody

CATALOG NO: A1307-100

ALTERNATE NAMES: Opdivo

AMOUNT: 100 µg

IMMUNOGEN: Human programmed cell death 1 receptor (PD-1)

HOST/ISOTYPE: Human IgG4

CLONALITY: Monoclonal

SOURCE: CHO cells

ENDOTOXIN LEVELS: < 0.05 EU/ml

PURIFICATION: IgG purified from CHO culture supernatant by protein A chromatography

SPECIES REACTIVITY: Human

FORM: Liquid

FORMULATION: Supplied in phosphate buffered saline, pH 7.4

STORAGE CONDITIONS: For long term storage store at -20°C. Once thawed, keep it at 4°C.

SPECIFICITY: Opdivo (bio-similar) is a human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Opdivo (biosimilar) is an IgG4 Kappa immunoglobulin that has a calculated molecular mass of 146 kDa.

DESCRIPTION: Nivolumab, trade name Opdivo, is a medication used to treat cancer. It is used as a first line treatment for inoperable or metastatic melanoma in combination with ipilimumab if the cancer does not have a mutation in BRAF, as a second-line treatment following treatment with ipilimumab and if the cancer has a mutation in BRAF, with a BRAF inhibitor, as a second-line treatment for squamous non-small cell lung cancer, and as a second-line treatment for renal cell carcinoma.

APPLICATION: Neutralization: 0.1-1 µg/ml, ELISA: 1 µg/ml

Note: This information is only intended as a guide. The optimal dilutions must be determined by the user.

FOR RESEARCH USE ONLY! Not to be used on humans.